Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

PROSERA Study

Monday, August 26, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The PROSERA study is a phase 3 clinical trial evaluating seralutinib for adults with Pulmonary Arterial Hypertension (PAH). This research aims to assess the drug's effectiveness and safety in treating this condition. The study is part of ongoing efforts to improve treatment options for PAH patients.
Price reaction · baseline $0.941 (2024-08-26T17:30:00.000Z) · hit during market hours · clean, no other GOSS news in the window
day 0 close · peak
-1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • The PROSERA study is a phase 3 trial, indicating advanced research.
  • Seralutinib is being investigated for treating Pulmonary Arterial Hypertension.
  • The study aims to provide more information on the efficacy of seralutinib.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

PROSERA Study
The PROSERA study is a phase 3 clinical research study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
PROSERA Study on clinicaltrials.gov More Information about PROSERA
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the PROSERA study?

The PROSERA study is a phase 3 clinical trial assessing seralutinib for adults with PAH.

What condition does seralutinib target?

Seralutinib is being investigated for treating Pulmonary Arterial Hypertension (PAH).

What phase is the PROSERA study?

The PROSERA study is a phase 3 clinical research study.

Who can participate in the PROSERA study?

The study is designed for adults diagnosed with Pulmonary Arterial Hypertension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib Pulmonary Arterial Hypertension clinical trial phase 3
Last updated: Aug 26, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →